Oxidative stress is associated with the degeneration of both motor neurons and skeletal muscles in amyotrophic lateral sclerosis (ALS). A free radical scavenger edaravone has been proven as a therapeutic drug for ALS patients, but the neuroprotective mechanism for the oxidative stress of ALS has not been fully investigated. In this study, we investigated oxidative stress in ALS model mice bearing both oxidative stress sensor nuclear erythroid 2-related factor 2 (Nrf2) and G93A-human Cu/Zn superoxide dismutase (Nrf2/G93A) treated by edaravone. In vivo Nrf2 imaging analysis showed the accelerated oxidative stress both in spinal motor neurons and lower limb muscles of Nrf2/G93A mice according to disease progression in addition to the enhancement of serum oxidative stress marker dROMS. These were significantly alleviated by edaravone treatment accompanied by clinical improvements (rotarod test). The present study suggests that in vivo optical imaging of Nrf2 is useful for detecting oxidative stress in ALS, and edaravone alleviates the degeneration of both motor neurons and muscles related to oxidative stress in ALS patients.
| INTRODUC TI ON
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of central and peripheral motor neurons. The majority (90%) of ALS cases are sporadic, while frequent genetic mutations of familial ALS occur in the Cu/Zn superoxide dismutase (SOD1) (Aoki et al., 1993; Rosen, 1993) and TAR DNA binding protein 43 (TDP-43) (Arai et al., 2006; Kabashi et al., 2008) , and a hexanucleotide repeat expansion of C9orf72 gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . Although many pathological mechanisms cause the disease, oxidative stress is associated with motor neuron degeneration in ALS related to SOD1, TDP-43, and the C9orf72 gene (Lopez-Gonzalez et al., 2016; Milani, Ambrosi, Gammoh, Blandini, & Cereda, 2013; Moujalled et al., 2017) .
The nuclear erythroid 2-related factor 2 (Nrf2)/Kelch-like ECHassociated protein 1 (Keap1) system is a major oxidative stress sensor; Nrf2 is released from Keap1 in cytoplasm, translocate into nucleus and binds to the antioxidant response element (ARE) under oxidative stress, but Nrf2 combined with Keap1 is rapidly degraded under normal condition (Mead et al., 2013; Petri, Korner, & Kiaei, 2012) . We previously reported the Nrf2 activation in spinal motor neurons of ALS model mice bearing G93A-SOD1 (Mimoto et al., 2012) , and another report showed a higher ARE activation in skeletal muscles than the spinal cords of the same model mice (Kraft, Resch, Johnson, & Johnson, 2007) . ALS skeletal muscles are involved in several pathogeneses, including oxidative stress (Loeffler, Picchiarelli, Dupuis, & Gonzalez De Aguilar, 2016; Tsitkanou, Della Gatta, & Russell, 2016) , but previous reports rarely focused on the contribution of ALS muscles to the pathological process.
For treating oxidative damage in acute ischemic stroke, a free radical scavenger edaravone has been widely used as a neuroprotective drug (Abe, Yuki, & Kogure, 1988; Edaravone Acute Infarction Study, 2003) . Recently, edaravone was proven as a therapeutic drug for ALS, improving motor functions of SOD1 mice and rats and ALS patients (Abe et al., 2014; Aoki et al., 2011; Ito et al., 2008; Writing, & Edaravone, 2017; Yoshino, & Kimura,, 2006) . However, the neuroprotective mechanism of edaravone for the oxidative stress of ALS has not been fully investigated. In the present study, therefore, we investigated oxidative stress in the spinal cords and skeletal muscles of ALS model mice carrying oxidative stress sensor Nrf2 with in vivo imaging of Nrf2 to observe the possible protective effect of edaravone.
| E XPERIMENTAL PROCEDURE S

| Animal models and drug treatments
All experimental procedures were carried out according to the guidelines of the Animal Care and Use Committee of the Graduate School of Medicine, Dentistry and Pharmaceutical Sciences of Okayama University (approval #OKU-2015158). Keap1-dependent oxidative stress detector No-48 (Nrf2) (Oikawa, Akai, Tokuda, & Iwawaki, 2012 ) and G93A-human SOD1 (Gurney et al., 1994) transgenic (Tg) mice were obtained from TransGenic Inc. (Fukuoka, Japan) and Jackson Laboratories (Bar Harbor, ME, USA), respectively. Double transgenic mice overexpressing Nrf2 and G93A-SOD1 (Nrf2/G93A) were derived by breeding mice hemizygously for each Nrf2 transgene with G93A-SOD1 mice. Nrf2/G93A double Tg mice experienced disease onset at around 91 days of age (Ohta et al., 2011) , and were randomly divided into two experimental groups: Nrf2/G93A mice treated with vehicle (n = 15; 8 male and 7 female), and Nrf2/G93A Tg mice treated with edaravone (Mitsubishi Tanabe Pharma, Osaka, Japan; n = 14; 6 male and 8 female 
| Clinical scores and in vivo optical imaging
For clinical analyses, survival was checked every day, and body weight (BW) and the rotarod score were measured once a week. These analyses were started at 84 days of age (presymptomatic stage) in Nrf2/G93A mice treated with vehicle or edaravone according to our previous reports (Ohta et al., 2008 (Ohta et al., , 2006 (Ohta et al., , 2016 . In the rotarod test, three trials were performed and the best result was recorded. End-stage was defined as the time at which a mouse could not right itself within 30 s when placed on its side.
In vivo bioluminescent imaging was performed in Nrf2 mice and Nrf2/G93A mice treated with vehicle or edaravone using the IVIS spectrum imaging system (PerkinElmer Inc., Billerica, MA, USA). At 84, 105 (early symptomatic stage) and 126 (late stage) days of age (each n = 6-12), mice were intraperitoneally injected with 300 mg/ kg of D-luciferin (OZ Biosciences, San Diego, CA, USA) dissolved in phosphate-buffered saline (PBS) 15 min before in vivo optical imaging. Under constant anesthesia, the skin of back and lower limbs (LL) was then opened to show the vertebrae and muscles of LL. In the preliminary experiment, mice died too early after laminectomy to detect direct bioluminescent signals from the spinal cords (data not shown). Therefore, we analyzed bioluminescent signals of spinal cords through vertebrae at a 3-min exposure time after incision.
In vivo optical signals of oxidative stress in Nrf2/G93A mice were observed as bioluminescence of exogenous human Nrf2 fragment combined with flag-tagged luciferase, induced by endogenous Nrf2 dissociated from Keap1 (Oikawa et al., 2012) . Bioluminescent signals of the spinal cords and bilateral LL were measured using regions of interest (ROIs), and emission intensity was expressed as the total flux of photons (photons/s) by LivingImage software (PerkinElmer) . (Kusaki et al., 2017; Tamaki, Tomofuji, Ekuni, Yamanaka, & Morita, 2011) .
| Blood serum analyses and kidney weight
The serum oxidative stress (OS) index was calculated by dividing the d-ROMs value by the OXY value and multiplying by 1,000 (Crowley, Po, Celi, & Muscatello, 2013; Jothery et al., 2016) .
| Immunofluorescence of the quadriceps muscle and spinal cord
The quadriceps muscles and the lumbar cord spanning L4-L5 were Invitrogen, B13423). They were then mounted using Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) according to our previous reports (Ohta et al., 2011 (Ohta et al., , 2016 .
The following antibodies were used: goat anti-vesicular acetylcholine (Table 1 ). Samples were observed by confocal laser microscopy (LSM780, Zeiss, Oberkochen, Germany).
| Quantitative analyses of muscle and spinal cord sections
For the quantitative analysis of myofiber size, or the number of endogenous (stained with anti-Nrf2 antibody) or exogenous Nrf2
(stained with anti-Luc antibody) positive myofibers, about 180 myofibers from three hematoxylin and eosin (HE) stained or immunostained quadriceps muscle sections per mouse (n = 5-6 mice for each group) were analyzed by an investigator blinded to the treatment conditions. For the analyses of denervation, 100 neuromuscular junctions (NMJ) from each mouse were analyzed (n = 5-6 mice for each group).
For the analysis of the number of α-motor neurons stained with both ChAT and NeuN, and endogenous or exogenous Nrf2 positive cells, and the semiquantitative evaluation of immunoreactivity for GFAP and Iba1, four lumbar cord sections from each mouse (n = 5-6 mice for each group) were analyzed using ImageJ by an investigator blinded to the treatment conditions.
| Statistical analysis
Data were analyzed in GraphPad Prism (version 6.0, GraphPad Software Inc., San Diego, CA, SCR_002798) and expressed as means ± SD. Statistical comparisons of immunoreactivity for GFAP and Iba1 between Nrf2/SOD1 treated with vehicle and edaravone were performed using an unpaired t-test. Statistical comparisons of bioluminescent signals of in vivo imaging, kidney weight, blood serum analyses, and other histological data were performed using one-way ANOVA, followed by a Tukey-Kramer post hoc comparison for normally disturbed data, and with Kruskall-Wallis, followed by a Dunn's post hoc comparison for non-normally disturbed data. Statistical comparisons of BW and rotarod score were performed using twoway repeated measure ANOVA. Kaplan-Meier survival analysis and the log-rank test were used for survival. Statistical significance was set at p < 0.05.
| RE SULTS
| Clinical scores in Nrf2/G93A mice
The mean survival time of Nrf2/G93A mice treated with edaravone (141.2 ± 8.9 days, n = 13, 5 male and 8 female) was almost same as mice treated with vehicle (138.9 ± 8.4 days, n = 15, 8 male and 7 female) (n = 28, p = 0.404, Log-rank test, Figure 1a ). There was no sex difference of mean survival time of Nrf2/G93A mice between vehicle and edaravone (male; vehicle 139.0 ± 6.9 days, edaravone 144.6 ± 11.8 days, female; vehicle 138.9 ± 8.4 days, edaravone 141.2 ± 8.9 days). Nrf2/G93A mice treated with vehicle (n = 11, 5 male and 6 female) showed a gradual decrease in body weight after 
| Mouse serum analyses for renal function and oxidative stress
The kidney weight of Nrf2/G93A mice treated with vehicle (n = 6, 1 male and 5 female) and edaravone (n = 6, 3 male and 3 female) was significantly less than that of WT (n = 11, 4 male and 7 female) and Nrf2 mice (n = 7, 3 male and 4 female) (F 3, 26 = 9.58, n = 30, p < 0.001, one-way ANOVA, p < 0.01, Tukey-Kramer post hoc, Figure 2a ).
Serum renal function showed significant elevation of BUN in Nrf2/ G93A mice with vehicle (n = 5, 2 male and 3 female) and edaravone (n = 3, 3 female) than that in WT (n = 10, 3 male and 7 female) and Nrf2 mice (n = 7, 3 male and 4 female) (H = 14.16, n = 25, p = 0.003, Kruskall-Wallis, p < 0.01, Dunn's post hoc, Figure 2b ), while there were no significant differences in the serum Cr level between the four groups (WT; n = 10, 3 male and 7 female, Nrf2; n = 7, 3 male and 4 female, vehicle; n = 6, 3 male and 3 female, edaravone; n = 4, 1 male and 3 female, H = 7.19, n = 27, p = 0.066, Kruskall-Wallis, Figure 2c ). There was no sex difference in kidney weight and serum renal function (data not shown).
The serum markers of oxidative stress dROMs and the OS index were significantly elevated in Nrf2/G93A mice treated with vehicle (vehicle; n = 7, 2 male and 5 female, edaravone; n = 6, 3 male and 3 female) compared with WT (n = 5, 4 male and 1 female) and Nrf2 mice (n = 7, 3 male and 4 female) (dROMs: 
| In vivo optical imaging of oxidative stress of Nrf2/G93A mice
In Nrf2 mice (84 and 105 days of age; n = 6, 4 male and 2 female, 126 days of age; n = 7, 5 male and 2 female), an evident signal was not observed over the spine or LL at three time points ( 
| Myofiber size and denervation in quadriceps muscles of Nrf2/G93A mice
Compared with WT (n = 5, 3 male and 2 female) and Nrf2 mice (n = 5, 2 male and 3 female), HE staining of quadriceps muscles showed marked or mild neurogenic myofiber atrophy in Nrf2/G93A mice with vehicle (n = 6, 1 male and 5 female) and edaravone (n = 6, 3 male and 3 female), respectively, at 130 days ( Figure 4a , Supple Figure   S2 ), when strong bioluminescent signals appeared in vivo (Figure 3f ).
Small myofibers (<20 µm diameter) dominated in Nrf2/G93A mice with vehicle compared with WT and Nrf2 mice (<10 µm diameter: 
| D ISCUSS I ON
In the present study, the elevation of oxidative stress in the spinal cord and LL muscles of symptomatic Nrf2/G93A mice was first shown with in vivo bioluminescent Nrf2 signals ( Figure 3) and with Oxidative stress is a major neuropathological mechanism for motor neuron degeneration in ALS associated with SOD1, TDP-43, and the C9orf72 gene (Lopez-Gonzalez et al., 2016; Milani et al., 2013; Moujalled et al., 2017) . The Nrf2-Keap1 system is the oxidative stress sensor (Mead et al., 2013; Petri et al., 2012) , and we previously reported activation of Nrf2 expression in lumbar motor neurons of G93A-SOD1 mice in spinal cord sections.
However, we did not examine the muscles (Mimoto et al., 2012) .
A previous report using the same model mice showed a higher activation of ARE expression in LL muscles than in the spinal cord ALS skeletal muscles are involved in oxidative stress, mitochondrial dysfunction and bioenergetic disturbances (Loeffler et al., 2016; Tsitkanou et al., 2016) . In the present study, Nrf2/G93A mice showed neurogenic myofiber atrophy, denervated NMJ and Nrf2 expression of small quadriceps myofibers in LL, which were significantly alleviated by edaravone, except for the NMJ denervation (Figures 3-5 ). This suggests that edaravone directly reduced LL muscle degeneration due to oxidative stress. PGC1α regulated Nrf2 expression and mitochondrial biogenesis, and improved muscle function in G37R-SOD1 mice (Da Cruz et al., 2012; Do, Kim, Choi, & Jeong, 2014) . However, PGC1α expression was decreased in skeletal muscles both of G93A-SOD1 mice and ALS patients unlike healthy subjects (Thau et al., 2012) .
Furthermore, another Nrf2 regulating factor HDAC4 was correlated with disease progression in ALS patients (Bruneteau et al., 2013; Singh et al., 2013) . In the present study, both PGC1α and HDAC4 were expressed preferentially in Nrf2 expressing myofibers of Nrf2/SOD1 mice ( Figure 6 ), suggesting the Nrf2 upregulation for oxidative stress was independent in skeletal muscles, and the Nrf2 pathway of skeletal muscles can be an alternative therapeutic target in ALS.
A free radical scavenger edaravone was proven as a neuroprotective drug and is widely used for the treatment of acute ischemic strokes (Abe et al., 1988; Edaravone Acute Infarction Study, 2003) . Previous reports showed that edaravone reduced the oxidative stress marker 3-nitrotyrosine in the spinal cord of G93A-SOD1 mice and cerebral cerebrospinal fluid of ALS patients (Ito et al., 2008; Yoshino & Kimura, 2006) . It also improved motor function of SOD1 mice and rats as well as ALS patients (Abe et al., 2014; Aoki et al., 2011; Ito et al., 2008; Writing & Edaravone, 2017; Yoshino & Kimura, 2006) . In the present study, edaravone treatment significantly reduced the oxidative stress serum markers dROM and the OS index, and Nrf2 expression in spinal motor neurons and LL myofibers (Figures 2d, e, 3, 5, 8) . It also reduced the expressions of PGC1α and HDAC4 in myofibers (Figure 6 ), suggesting edaravone treatment enhanced mitochondrial function and muscle development (Loeffler et al., 2016; Petri et al., 2012; Thau et al., 2012) . Furthermore, edaravone treatment (Figures 1c, 4, 7) . This suggests that the inhibition of oxidative stress is beneficial to reduce degeneration both in the spinal cord and skeletal muscles of ALS.
While edaravone treatment did not improve the survival of ALS model mice (Figure 1a ) as previously reported (Aoki et al., 2011; Ito et al., 2008) , which suggests that inhibition of oxidative stress is not beneficial to prolong life span in ALS model mice. However, improving motor performance and muscle atrophy due to edara- As previously reported (Aoki et al., 2011) , edaravone treatment improved the motor performance in male mice, but not in female (Supple Figure 1) , although it ameliorated the oxidative stress and the degeneration of skeletal muscles and spinal cords in both sex (data not shown). The reason might be due to protective effects of estrogen for mitochondria under oxidative stress in female (Cacabelos et al., 2016; Kruman, Pedersen, Springer, & Mattson, 1999) , but further studies using more numbers of each sex are needed to confirm the sex difference on benefits of edaravone treatment.
In conclusion, we studied accelerated oxidative stress both in spinal motor neurons and LL myofibers of SOD1 mice according to disease progression by serum, in vivo optical and immunofluorescent analyses. Edaravone successfully reduced the degeneration of motor neurons and myofibers by inhibiting oxidative stress. In vivo optical imaging of Nrf2 may be useful for evaluating antioxidative therapies for oxidative stress in ALS patients.
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